Vincerx Pharma (VINC) announced that the previously signed binding Term Sheet between Vincerx, Oqory, and Vivasor for a reverse merger transaction has been terminated. As a result, the board of directors will reassess the company’s strategic alternatives, including out-licensing, merger and acquisition opportunities, the sale of assets and technologies, and winding down operations, among other potential transactions. As of February 26, the company had approximately $3.9M in cash. The company’s cash runway is expected to extend through late Q2 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VINC:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue